XHKG
3332
Market cap25mUSD
Oct 07, Last price
0.21HKD
1D
-0.95%
1Q
51.82%
Jan 2017
-87.54%
IPO
-92.30%
Name
Nanjing Sinolife United Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nanjing Sinolife United Company Limited functions as an investment holding entity primarily involved in the manufacturing, processing, and global distribution of nutritional supplements. Its operations span the People's Republic of China, Australia, New Zealand, Vietnam, and various international markets. The firm additionally produces and markets cosmetics and skincare items, while also undertaking the trading, retail, and testing of pre-packaged health food products. Products are sold under well-known brands such as Good Health, Zhongsheng, Hejian, and Cobayer, primarily via its comprehensive network of retail outlets. Distribution also encompasses sales through distributors, television shopping channels, online e-commerce platforms, chain pharmacies, specialized health food supermarkets, and tourist souvenir shops. The company, which has been headquartered in Nanjing, China, since its establishment in 1999.
Key people
Pinghu Gui
Executive Chairman of the Board · since 1999
Bin Li
Chief Financial Officer · since 2013
Jun Wu
Financial Controller · since 2013
Yuan Zhang
Chief Executive Officer, Executive Director · since 2011
Feifei Zhu
Executive Director · since 2012
Hui Zhi
Manager - Human Resources, Company Secretary · since 2012
Jiming Song
Compliance Officer · since 2005
Min Yu
Chairman of the Board of Supervisors · since 2012
Joint Company Secretary · since 2024
Jianming Cheng
Non-Executive Independent Director · since 2024
Bangyin Ye
Non-Executive Independent Director · since 2024
Bo Yu
Independent Non-Executive Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||